Analysts Set Avantor, Inc. (NYSE:AVTR) Price Target at $12.47

Shares of Avantor, Inc. (NYSE:AVTR) have earned a consensus rating of “Hold” from the eighteen brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and two have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $12.4706.

Several brokerages have commented on AVTR. Morgan Stanley raised their target price on Avantor from $10.00 to $14.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Royal Bank Of Canada increased their price target on shares of Avantor from $9.00 to $14.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. Jefferies Financial Group upgraded shares of Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price objective for the company in a research report on Wednesday, July 29th. Citigroup boosted their price objective on shares of Avantor from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Finally, Barclays boosted their price objective on shares of Avantor from $7.00 to $8.00 and gave the company an “underweight” rating in a research note on Wednesday, June 24th.

Avantor Trading Down 2.2%

Shares of AVTR stock opened at $15.51 on Friday. The stock has a market capitalization of $10.49 billion, a price-to-earnings ratio of -18.46, a PEG ratio of 11.97 and a beta of 0.89. The company’s fifty day simple moving average is $13.63 and its two-hundred day simple moving average is $10.36. Avantor has a 1 year low of $7.26 and a 1 year high of $16.05. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.78 and a quick ratio of 1.18.

Avantor (NYSE:AVTR) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.02. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.The firm had revenue of $1.69 billion during the quarter, compared to analyst estimates of $1.61 billion. During the same period last year, the company earned $0.24 earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, analysts anticipate that Avantor will post 0.81 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Private Management Group Inc. raised its stake in shares of Avantor by 50.4% during the fourth quarter. Private Management Group Inc. now owns 2,456,859 shares of the company’s stock worth $28,156,000 after acquiring an additional 823,572 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Avantor in the 2nd quarter valued at $800,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Avantor in the 2nd quarter valued at $805,000. Assenagon Asset Management S.A. grew its holdings in shares of Avantor by 425.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 556,871 shares of the company’s stock valued at $5,513,000 after purchasing an additional 450,801 shares during the last quarter. Finally, Brickwood Asset Management LLP grew its holdings in shares of Avantor by 6,891.9% during the 4th quarter. Brickwood Asset Management LLP now owns 3,184,043 shares of the company’s stock valued at $36,489,000 after purchasing an additional 3,138,504 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

About Avantor

Avantor, Inc (NYSE: AVTR) is a global provider of products and services used in the life sciences, healthcare and advanced technology industries. The company supports research, drug discovery, biopharmaceutical production, clinical and diagnostic activities, and other laboratory-based applications.

Its offerings include laboratory chemicals and reagents, consumables, equipment, instruments, production materials and related services. Avantor also provides supply-chain, procurement and other technical solutions designed to help customers manage laboratory and manufacturing operations.

Avantor serves customers across pharmaceutical and biopharmaceutical companies, healthcare providers, academic and government institutions, medical laboratories and industrial businesses.